Compare KEQU & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | VTVT |
|---|---|---|
| Founded | 1906 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.6M | 127.0M |
| IPO Year | N/A | 2015 |
| Metric | KEQU | VTVT |
|---|---|---|
| Price | $37.62 | $41.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $51.33 |
| AVG Volume (30 Days) | 7.5K | ★ 14.6K |
| Earning Date | 12-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.94 | N/A |
| Revenue | ★ $285,515,000.00 | $17,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.76 | ★ N/A |
| Revenue Growth | ★ 43.02 | N/A |
| 52 Week Low | $30.33 | $13.20 |
| 52 Week High | $71.33 | $43.08 |
| Indicator | KEQU | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 78.62 |
| Support Level | $37.10 | $38.22 |
| Resistance Level | $38.29 | $41.49 |
| Average True Range (ATR) | 1.04 | 2.39 |
| MACD | 0.09 | 0.47 |
| Stochastic Oscillator | 34.22 | 97.62 |
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.